Cargando…

Body Mass Index, Weight Loss, and Mortality Risk in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Focus on EGFR Mutation

Body mass index (BMI) influences the prognosis of patients with non-small cell lung cancer (NSCLC), including both early-stage and late-stage NSCLC patients that are undergoing chemotherapies. However, earlier research on the relationship between BMI and survival in patients taking epidermal growth...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yu-Mu, Lai, Chien-Hao, Lin, Chiung-Yu, Tsai, Yi-Hsuan, Chang, Ya-Chun, Chen, Hung-Chen, Tseng, Chia-Cheng, Chang, Huang-Chih, Huang, Kuo-Tung, Chen, Yung-Che, Fang, Wen-Feng, Wang, Chin-Chou, Chao, Tung-Ying, Lin, Meng-Chih
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8622618/
https://www.ncbi.nlm.nih.gov/pubmed/34836017
http://dx.doi.org/10.3390/nu13113761
_version_ 1784605735899889664
author Chen, Yu-Mu
Lai, Chien-Hao
Lin, Chiung-Yu
Tsai, Yi-Hsuan
Chang, Ya-Chun
Chen, Hung-Chen
Tseng, Chia-Cheng
Chang, Huang-Chih
Huang, Kuo-Tung
Chen, Yung-Che
Fang, Wen-Feng
Wang, Chin-Chou
Chao, Tung-Ying
Lin, Meng-Chih
author_facet Chen, Yu-Mu
Lai, Chien-Hao
Lin, Chiung-Yu
Tsai, Yi-Hsuan
Chang, Ya-Chun
Chen, Hung-Chen
Tseng, Chia-Cheng
Chang, Huang-Chih
Huang, Kuo-Tung
Chen, Yung-Che
Fang, Wen-Feng
Wang, Chin-Chou
Chao, Tung-Ying
Lin, Meng-Chih
author_sort Chen, Yu-Mu
collection PubMed
description Body mass index (BMI) influences the prognosis of patients with non-small cell lung cancer (NSCLC), including both early-stage and late-stage NSCLC patients that are undergoing chemotherapies. However, earlier research on the relationship between BMI and survival in patients taking epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) yielded contradictory results. These publications either had a limited number of patients or were getting TKIs in various lines of therapy, which might explain why the outcomes were contradictory. As a result, we undertook retrospective study to examine the effect of BMI on survival outcomes in patients with advanced EGFR mutant NSCLC receiving first-line EGFR-TKIs. We also compared the findings to those with wild-type EGFR. Between November 2010 and March 2014, 513 patients with advanced NSCLC were enrolled in the study. According to the adjusted BMI cut-off point for Asia, 35 out of 513 (6.8%) patients were underweight (BMI < 18.5 kg/m(2)), whereas 197 (38.4%) were overweight (BMI > 24 kg/m(2)). Overweight patients with wild-type EGFR exhibited longer progression-free survival (4.6 vs. 2.1 months, p = 0.003) and overall survival (OS) (8.9 vs. 4.3 months, p = 0.003) than underweight patients. Overweight patients with EGFR mutations had a longer OS than normal-weight patients (23.0 vs. 20.2 months, p = 0.025). Bodyweight reduction was related to a shorter OS in both the mutant EGFR patients (17.1 vs. 30.5 months, p < 0.001) and the wild-type EGFR patients (7.8 vs. 18.7 months, p < 0.001). In conclusion, advanced stages NSCLC patients with a lower BMI and early weight loss had a worse outcome that was independent of EGFR mutation status.
format Online
Article
Text
id pubmed-8622618
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86226182021-11-27 Body Mass Index, Weight Loss, and Mortality Risk in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Focus on EGFR Mutation Chen, Yu-Mu Lai, Chien-Hao Lin, Chiung-Yu Tsai, Yi-Hsuan Chang, Ya-Chun Chen, Hung-Chen Tseng, Chia-Cheng Chang, Huang-Chih Huang, Kuo-Tung Chen, Yung-Che Fang, Wen-Feng Wang, Chin-Chou Chao, Tung-Ying Lin, Meng-Chih Nutrients Article Body mass index (BMI) influences the prognosis of patients with non-small cell lung cancer (NSCLC), including both early-stage and late-stage NSCLC patients that are undergoing chemotherapies. However, earlier research on the relationship between BMI and survival in patients taking epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) yielded contradictory results. These publications either had a limited number of patients or were getting TKIs in various lines of therapy, which might explain why the outcomes were contradictory. As a result, we undertook retrospective study to examine the effect of BMI on survival outcomes in patients with advanced EGFR mutant NSCLC receiving first-line EGFR-TKIs. We also compared the findings to those with wild-type EGFR. Between November 2010 and March 2014, 513 patients with advanced NSCLC were enrolled in the study. According to the adjusted BMI cut-off point for Asia, 35 out of 513 (6.8%) patients were underweight (BMI < 18.5 kg/m(2)), whereas 197 (38.4%) were overweight (BMI > 24 kg/m(2)). Overweight patients with wild-type EGFR exhibited longer progression-free survival (4.6 vs. 2.1 months, p = 0.003) and overall survival (OS) (8.9 vs. 4.3 months, p = 0.003) than underweight patients. Overweight patients with EGFR mutations had a longer OS than normal-weight patients (23.0 vs. 20.2 months, p = 0.025). Bodyweight reduction was related to a shorter OS in both the mutant EGFR patients (17.1 vs. 30.5 months, p < 0.001) and the wild-type EGFR patients (7.8 vs. 18.7 months, p < 0.001). In conclusion, advanced stages NSCLC patients with a lower BMI and early weight loss had a worse outcome that was independent of EGFR mutation status. MDPI 2021-10-24 /pmc/articles/PMC8622618/ /pubmed/34836017 http://dx.doi.org/10.3390/nu13113761 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chen, Yu-Mu
Lai, Chien-Hao
Lin, Chiung-Yu
Tsai, Yi-Hsuan
Chang, Ya-Chun
Chen, Hung-Chen
Tseng, Chia-Cheng
Chang, Huang-Chih
Huang, Kuo-Tung
Chen, Yung-Che
Fang, Wen-Feng
Wang, Chin-Chou
Chao, Tung-Ying
Lin, Meng-Chih
Body Mass Index, Weight Loss, and Mortality Risk in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Focus on EGFR Mutation
title Body Mass Index, Weight Loss, and Mortality Risk in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Focus on EGFR Mutation
title_full Body Mass Index, Weight Loss, and Mortality Risk in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Focus on EGFR Mutation
title_fullStr Body Mass Index, Weight Loss, and Mortality Risk in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Focus on EGFR Mutation
title_full_unstemmed Body Mass Index, Weight Loss, and Mortality Risk in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Focus on EGFR Mutation
title_short Body Mass Index, Weight Loss, and Mortality Risk in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Focus on EGFR Mutation
title_sort body mass index, weight loss, and mortality risk in advanced-stage non-small cell lung cancer patients: a focus on egfr mutation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8622618/
https://www.ncbi.nlm.nih.gov/pubmed/34836017
http://dx.doi.org/10.3390/nu13113761
work_keys_str_mv AT chenyumu bodymassindexweightlossandmortalityriskinadvancedstagenonsmallcelllungcancerpatientsafocusonegfrmutation
AT laichienhao bodymassindexweightlossandmortalityriskinadvancedstagenonsmallcelllungcancerpatientsafocusonegfrmutation
AT linchiungyu bodymassindexweightlossandmortalityriskinadvancedstagenonsmallcelllungcancerpatientsafocusonegfrmutation
AT tsaiyihsuan bodymassindexweightlossandmortalityriskinadvancedstagenonsmallcelllungcancerpatientsafocusonegfrmutation
AT changyachun bodymassindexweightlossandmortalityriskinadvancedstagenonsmallcelllungcancerpatientsafocusonegfrmutation
AT chenhungchen bodymassindexweightlossandmortalityriskinadvancedstagenonsmallcelllungcancerpatientsafocusonegfrmutation
AT tsengchiacheng bodymassindexweightlossandmortalityriskinadvancedstagenonsmallcelllungcancerpatientsafocusonegfrmutation
AT changhuangchih bodymassindexweightlossandmortalityriskinadvancedstagenonsmallcelllungcancerpatientsafocusonegfrmutation
AT huangkuotung bodymassindexweightlossandmortalityriskinadvancedstagenonsmallcelllungcancerpatientsafocusonegfrmutation
AT chenyungche bodymassindexweightlossandmortalityriskinadvancedstagenonsmallcelllungcancerpatientsafocusonegfrmutation
AT fangwenfeng bodymassindexweightlossandmortalityriskinadvancedstagenonsmallcelllungcancerpatientsafocusonegfrmutation
AT wangchinchou bodymassindexweightlossandmortalityriskinadvancedstagenonsmallcelllungcancerpatientsafocusonegfrmutation
AT chaotungying bodymassindexweightlossandmortalityriskinadvancedstagenonsmallcelllungcancerpatientsafocusonegfrmutation
AT linmengchih bodymassindexweightlossandmortalityriskinadvancedstagenonsmallcelllungcancerpatientsafocusonegfrmutation